Form 4 for EXEL EXELIXIS, INC.
Accepted 2023-02-08 00:00:00 ET · period of report 2023-02-06 · accession 0000939767-23-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-08 | 2023-02-06 | EXEL | Haley Patrick J. | EVP, Commercial | M - OptEx | $4.20 | +25.0K | 279.4K | +10% | +$105.0K |
| D | 2023-02-08 | 2023-02-06 | EXEL | Haley Patrick J. | EVP, Commercial | S - Sale+OE | $17.37 | -25.0K | 254.4K | -9% | -$434.2K |
| D | 2023-02-08 | 2023-02-06 | EXEL | Haley Patrick J. | EVP, Commercial | M - OptEx | $0.00 | -25.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-06 | M | A | 25,000 | $4.20 | 279,414 | D | — | — | (F1) Includes 151,866 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| 2 | Common | Common Stock | 2023-02-06 | S | D | 25,000 | $17.37 | 254,414 | D | — | — | (F3) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.30 to $17.50. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. |
| 3 | Derivative | Option (right to buy) | 2023-02-06 | M | D | 25,000 | $0.00 | 0 | D | $4.20 · 2017-02-11 to 2023-02-10 | 25,000 Common Stock | (F5) The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. |